Tang Ching Lau

Lau Tang Ching

  • Associate Professor, Department of Medicine
  • Senior Consultant, Division of Rheumatology, University Medicine Cluster, National University Hospital
Administrative Appointment(s)
  • Vice-Dean (Education), NUS Yong Loo Lin School of Medicine
  • Group Director (Education Office), National University Hospital
Academic Qualifications
  • MBBS, National University of Singapore, Singapore
  • MRCP, Royal College of Physicians, United Kingdom
  • MMed (Int Med), National University of Singapore, Singapore
  • FAMS (Rheumatology), Academy of Medicine, Singapore
  • MMedical Science (Clinical Epidemiology), University of Newcastle, Australia
  • Graduate Diploma in Acupuncture, Singapore
Research Interest(s)
  • Osteoporosis
  • Pharmacoeconomic
  • Medical Education
Recent Publications
  • 1. Lim, J. W., Chee, S. X., Wong, W. J., He, Q. L., & Lau, T. C. (2018). Traditional Chinese medicine: Herb-drug interactions with aspirin. Singapore Medical Journal, 59(5), 230-239. doi:10.11622/smedj.2018051
  • 2. Ng, C. S., Lau, T. C., & Ko, Y. (2017). Cost of Osteoporotic Fractures in Singapore. Value in Health Regional Issues, 12, 27-35. doi:10.1016/j.vhri.2016.12.002
  • 3. Howe, H. S., Thong, B. Y. H., Kong, K. O., Chng, H. H., Lian, T. Y., Chia, F. L., . . . Leung, B. P. (2017). Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 189(3), 298-303. doi:10.1111/cei.12975
  • 4. Chandran, M., Cheen, M., Ying, H., Lau, T. C., & Tan, M. (2016). Dropping the Ball and Falling Off the Care Wagon. Factors Correlating With Nonadherence to Secondary Fracture Prevention Programs. Journal of Clinical Densitometry, 19(1), 117-124. doi:10.1016/j.jocd.2015.06.009
  • 5. Cheung, P. P., Lahiri, M., Teng, G. -G., Lui, N. -L., Chia, F. L., Koh, D. -R., . . . Leong, K. -H. (2017). Consensus development on eligibility of government subsidisation of biologic disease modifying anti-rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 20(10), 1517-1526. doi:10.1111/1756-185X.12707